IRIC discoveries have spurred major advances in understanding the development of cancer and opened the way to the creation of new, more targeted therapeutic solutions. Its publications are a reflection of these accomplishments. They also demonstrate the Institute’s drive and productivity.
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.Nature 2003-11-13;426(6963):186-9.
In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein.Nat. Med. 2003-11-01;9(11):1428-32.
Nuclear export of ERK3 by a CRM1-dependent mechanism regulates its inhibitory action on cell cycle progression.J. Biol. Chem. 2003-10-24;278(43):42615-24.
Phosphorylation of the MAPKKK regulator Ste50p in Saccharomyces cerevisiae: a casein kinase I phosphorylation site is required for proper mating function.Eukaryotic Cell 2003-10-01;2(5):949-61.
Bimodal regulation of RAF by CNK in Drosophila.EMBO J. 2003-10-01;22(19):5068-78.
An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development.EMBO Rep. 2003-10-01;4(10):964-8.
Unsuspected role of the brain morphogenetic gene Otx1 in hematopoiesis.Proc. Natl. Acad. Sci. U.S.A. 2003-09-02;100(18):10299-303.
Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis.Exp. Hematol. 2003-07-01;31(7):567-85.
Rapid turnover of extracellular signal-regulated kinase 3 by the ubiquitin-proteasome pathway defines a novel paradigm of mitogen-activated protein kinase regulation during cellular differentiation.Mol. Cell. Biol. 2003-07-01;23(13):4542-58.